跳至主要内容
临床试验/NCT04708431
NCT04708431招募中不适用

Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1 个研究点 分布在 1 个国家目标入组 650 人开始时间: 2021年4月29日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
650
试验地点
1
主要终点
To define and describe a comprehensive phenotype in 500 patients with androgen insensitivity

研究概览

简要总结

Background:

Androgen effects in humans are usually (but not always) mediated by the androgen receptor which is coded for by the androgen receptor gene (AR gene). Androgen Insensitivity Syndrome (AIS) is a rare condition in which the body cannot sense the male hormones in the blood or tissue. Both women and men can be affected by AIS. Researchers want to learn more about the health of people with AIS over time.

With a natural history study in individuals with AIS, data and tests may provide information regarding health risks (including the risks and benefits of gonadectomy and best ways to monitor for tumor) and optimal management of individuals with AIS as well as elucidate the role of the androgen receptor in human health. This study does not involve any interventions and we can provide clinical care while collecting data.

Objective:

The objective of this natural history study is to describe and define a comprehensive phenotype (characteristic) of patients with AIS based on confirmed androgen receptor (AR) gene difference. We will evaluate hormones, bone density and markers, cardiovascular and metabolic parameters, as well as quality of life and tumor formation risk and evaluation. The purpose is to obtain a better understanding of the overall health issues that people with AIS may have through the study procedures listed.

Eligibility:

People ages 8-99 with AIS and their adult relatives

Design:

Participants will go through a series of study procedures for data and specimen collection. This will be done to understand how AIS affects individuals since the androgen receptor is found in many tissues in the body including skin, bone, muscle, and the neurologic, immune and metabolic systems. All tests will be performed by skilled and trained study professionals.

Participants will be screened with:

Medical history

Physical exam

Medical record review

Lab tests.

Participants will have physical exams. Their body measurements will be taken. They will have blood and urine tests. They will have electrocardiograms to check heart health. They may complete questionnaires. They may have an Oral Glucose Tolerance Test.

Participants may have x-rays and HRpQCT scans taken of the hand, wrist, and other bones.

Participants will have body scans to measure bone thickness.

Participants will have magnetic resonance imaging (MRI) or sonogram of the pelvis. For MRI, they may get a contrast agent via intravenous (IV) catheter.

Adult participants may have the following:

MR elastography. It uses MRI and low-frequency vibrations to map stiffness of body tissues.

MR spectroscopy. It uses MRI to take pictures of chemicals in the liver and body fat.

Cardiac computed tomography scan. It uses x-rays to make pictures of the heart. Participants may get a contrast agent via IV.

Optional genital exam.

Optional one-time vaginal swab.

Participants will have visits every 1-2 years. Participation lasts indefinitely.

Adult relatives will also be invited to participate but will have only 1 visit. It will include some of the above tests.

详细描述

Study Description: This is a natural history study of individuals with androgen receptor gene abnormalities.

Objectives:

Primary Objectives:

To define and describe a comprehensive phenotype of patients with androgen insensitivity (based on confirmed androgen receptor

(AR) gene difference), including hormonal, metabolic, immunologic, and cardiovascular aspects of AIS, as well as quality life and tumor formation risk and evaluation.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
8 Years 至 99 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • INCLUSION CRITERIA:
  • Inclusion Criteria for AIS Subjects
  • In order to be eligible to participate in this study, an individual must meet all the following criteria:
  • Individuals ages 8-99 years old with known androgen insensitivity based on pathologic androgen receptor gene mutation or based on clinical diagnosis of complete androgen insensitivity (CAIS) based on 46 XY karyotype, presence of testis, absence of uterus, high testosterone without signs of virilization at birth or during puberty and/or multiple members in the family also presenting with clinical CAIS.
  • Identify as male or female
  • Patients with both complete, partial, and mild androgen insensitivity are eligible
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Ability of subject or guardian to understand and the willingness to sign and date a written informed consent document.
  • Inclusion Criteria for Relative of AIS Subjects
  • 1) Adult Relatives of patients with AIS

排除标准

  • Exclusion Criteria for AIS Subjects
  • An individual who meets any of the following criteria will be excluded from participation in this study: Patients with other diagnoses such as partial or complete gonadal dysgenesis, 5-alpha reductase deficiency, and 46 XY. If, following a diagnostic work-up, a patient is determined to have causes for 46 XY DSD other than androgen insensitivity; they will no longer be followed on this protocol. They will have the opportunity to continue care with the team under the Data Collection Protocol or may be referred to an expert or multidisciplinary DSD team in the community.
  • Patients with significant non-endocrine medical conditions.
  • Exclusion Criteria for Relative of AIS Subjects
  • 1) Patients with significant non-endocrine medical conditions.

研究组 & 干预措施

Female subjects relatives who are carriers of the AR gene difference

We will enroll 50 female subjects relatives AIS subjects who are carriers of the AR gene difference

Female subjects relatives who are not carriers of the AR gene

We will enroll 50 female subjects relatives of AIS subjects who are not carriers of the AR gene.

Healthy male subjects relatives

We will enroll 50 healthy male subjects of AIS relative subjects

Subjects with androgen receptor mutations

500 Subjects with confirmed androgen receptor mutations

结局指标

主要结局

To define and describe a comprehensive phenotype in 500 patients with androgen insensitivity

时间窗: End of study

Primary Objectives: To define and describe a comprehensive phenotype of patients with androgen insensitivity (based on confirmed androgen receptor (AR) gene difference), including hormonal, metabolic, immunologic, and cardiovascular aspects of the disease, as well as quality life and tumor formation risk and evaluation

次要结局

  • Evaluate Bone Health in individuals with Androgen Insensitivity(End of study)
  • Metabolic assessment in individuals with Androgen Insensitivity(End of study)
  • Gonadal Tumor evaluation in individuals with Androgen Insensitivity(End of study)
  • Quality of life measures (QoL) in individuals with Androgen Insensitivity(End of study)
  • Effects of hormone therapy in individuals with Androgen Insensitivity(End of study)
  • Effects of hormone therapy in individuals with Androgen Insensitivity(End of study)
  • Gonadal Tumor evaluation in individuals with Androgen Insensitivity(End of study)
  • Quality of life measures (QoL) in individuals with Androgen Insensitivity(End of study)
  • Evaluate Bone Health in individuals with Androgen Insensitivity(End of study)
  • Metabolic assessment in individuals with Androgen Insensitivity(End of study)

研究者

发起方
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
申办方类型
Nih
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

招募中
不适用
Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic prostate cancerCancer - ProstateProstate Cancer
ACTRN12619000720112GenesisCare40
进行中(未招募)
不适用
Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)Prostate Cancer
NCT03703778Chinese University of Hong Kong300
已完成
不适用
Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian ResponseAndrogen Receptor Gene OverexpressionNormal RespondersPoor Ovarian ResponseBologna Criteria
NCT03433768Aristotle University Of Thessaloniki67
进行中(未招募)
1 期
Dynamics of Androgen Receptor.MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036920Term: Prostate cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036911Term: Prostate cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036912Term: Prostate cancer stage 0System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036917Term: Prostate cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036919Term: Prostate cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036918Term: Prostate cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancer
EUCTR2014-000476-26-NLetherlands Cancer Institute50
尚未招募
2 期
Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA)prostate cancerprostate carcinoma10038597
NL-OMON40287Antoni van Leeuwenhoek Ziekenhuis60